• ABT-263 (Navitoclax): Applied Strategies for Apoptosis Assay

  2026-05-13

  Leverage ABT-263 (Navitoclax) for precise, reproducible apoptosis and senescence studies across cancer biology and regenerative workflows. This guide offers experimental optimization, troubleshooting, and protocol parameters based on authoritative research, empowering researchers to maximize the impact of this potent Bcl-2 inhibitor.

• Alternariol Triggers Hepatic Stellate Transdifferentiation a

  2026-05-12

  This study uncovers how Alternariol (AOH), a prevalent foodborne mycotoxin, induces hepatic stellate cell transdifferentiation and promotes liver fibrosis via NF-κB, ferroptosis, and autophagy pathways. Integrative lncRNA-mRNA omics and enzymatic detoxification analysis refine our understanding of AOH-driven hepatotoxicity and inform future toxin mitigation strategies.

• MG-132 (Z-LLL-al): Bridging Proteasome Inhibition to Transla

  2026-05-12

  Explore how MG-132 (Z-LLL-al) enables translational breakthroughs in apoptosis, cell cycle, and oxidative stress research. This thought-leadership article integrates mechanistic depth, protocol strategy, and recent advances in ubiquitin-proteasome system biology—guiding researchers through the nexus of evidence and innovation.

• HyperScribe™ Poly (A) Tailing Kit: Advancing mRNA Therapeuti

  2026-05-11

  Discover how the HyperScribe™ Poly (A) Tailing Kit empowers mRNA stability enhancement and translation efficiency improvement for therapeutic applications. This article offers a unique, evidence-based perspective on optimizing in vitro transcribed RNA for next-generation gene expression strategies.

• MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliu

  2026-05-11

  MTT, or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, is a benchmark tetrazolium salt for in vitro cell proliferation and metabolic activity assessment. Its reduction by cellular NADH-dependent oxidoreductases yields a quantifiable purple formazan product, directly correlating with cell viability. APExBIO’s high-purity MTT (SKU B7777) delivers reproducible, sensitive results in colorimetric cell viability assays.

• Latrunculin A: Applied Protocols for Actin Cytoskeleton Disr

  2026-05-10

  Latrunculin A from APExBIO delivers precise, rapid actin cytoskeleton disaggregation for advanced cell biology and virology workflows. This article provides data-driven protocol parameters, troubleshooting insights, and cross-domain perspectives, empowering researchers to dissect cytoskeletal dynamics and host-pathogen interactions with confidence.

• LDH Cytotoxicity Assay Kit: Quantitative Precision in Cell D

  2026-05-09

  Explore how the LDH Cytotoxicity Assay Kit enables precise cell cytotoxicity measurement, with in-depth analysis of assay mechanisms and practical guidance drawn from the latest nanocomposite biocompatibility research. This cornerstone article uniquely connects assay selection to quantitative structure–property insights.

• Lumiracoxib: Selective COX-2 Inhibitor for Ischemia Models

  2026-05-08

  Lumiracoxib offers unmatched selectivity and solubility for dissecting COX-2 pathways in tissue injury and revascularization models. Its time-sensitive inhibition profile enables researchers to parse the nuanced, stage-dependent effects of COX-2 on inflammation, angiogenesis, and muscle recovery.

• Hybridization and Pluripotency Network Rewiring in Xenopus l

  2026-05-08

  This study demonstrates that ancient hybridization in Xenopus laevis led to a functional rewiring of the pluripotency gene network across its two subgenomes, revealing asymmetric gene regulation but conserved embryonic expression levels. The findings advance our understanding of how genome duplication and regulatory divergence impact early vertebrate development and provide a valuable model for studying transcriptional control mechanisms.

• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Technical G

  2026-05-07

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) addresses the challenge of preserving protein phosphorylation during sample preparation by inhibiting alkaline and serine/threonine phosphatases, such as PP1 and PP2A. This product is best suited for workflows requiring accurate phosphoprotein analysis, including Western blot and kinase assays, but should not be used in applications where phosphatase activity is required for the experimental objective.

• MDV3100 (Enzalutamide): Applied Workflows in Prostate Cancer

  2026-05-07

  MDV3100 (Enzalutamide) delivers robust inhibition of androgen receptor signaling, empowering prostate cancer researchers to dissect apoptosis, resistance, and glycosaminoglycan-driven phenotypes. This guide distills protocol parameters, advanced applications, and troubleshooting strategies—anchored by the latest evidence on UGDH phosphorylation and therapeutic evasion.

• Y-27632: Precision ROCK Inhibitor for Cytoskeletal Modulatio

  2026-05-06

  Y-27632 is the benchmark ROCK inhibitor for dissecting cytoskeletal dynamics and optimizing advanced cell models. This guide details experimental workflows, application-specific enhancements, and troubleshooting strategies—empowering translational researchers to drive reproducible outcomes in cancer biology and regenerative studies.

• CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR

  2026-05-06

  This study uncovers how lactate secreted by cancer-associated fibroblasts (CAFs) fosters resistance to oxaliplatin in colorectal cancer by promoting cancer stemness through ANTXR1 lactylation. The findings provide mechanistic insights into tumor-stroma interactions and suggest novel avenues for overcoming chemoresistance.

• Microbiota–Tryptophan–AhR Axis in Intestinal Repair and UC

  2026-05-05

  Li et al. (2026) reveal that Huangqin decoction (HQD) repairs ulcerative colitis by reshaping gut microbiota and tryptophan metabolism, thereby activating the aryl hydrocarbon receptor (AhR) and promoting intestinal stem cell (ISC) differentiation. This work uncovers a mechanistic axis linking microbial metabolites and epithelial renewal, with implications for targeted interventions in barrier restoration.

• Atorvastatin in Ferroptosis: Advancing Cancer and Vascular R

  2026-05-05

  Explore how Atorvastatin, a potent HMG-CoA reductase inhibitor, is reshaping cholesterol metabolism research and illuminating new pathways in ferroptosis-driven cancer studies. This article uniquely deciphers recent findings and protocol implications for translational science.

383 records 7/26 page Previous Next First page 上5页 678910 下5页 Last page